A founder of a Massachusetts compounding pharmacy whose mold-tainted drugs sparked a deadly U.S. fungal meningitis outbreak in 2012 was resentenced on July 7 to 14-1/2 years in prison after a federal appeals court overturned his earlier 9-year term.

Despite the COVID-19 pandemic, the U.S. Food and Drug Administration is still working on approving drugs as best the regulatory agency can, although the FDA did recently announce the possibility of non-COVID-19 work being delayed. Here is a look at some target action dates on the schedule.

ATLANTA–(BUSINESS WIRE)–The Advisory Committee on Immunization Practices (ACIP), a sub committee of the Centers for Disease Control and Prevention (CDC) today recommended that newly available vaccinations to combat the “B” […]